# Aurobindo Pharma Ltd.

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/aurobindo-pharma-ltd
Canonical HTML page: https://getbiobrief.com/entity/aurobindo-pharma-ltd

## Timeline

- **2026-06-22**: FTC Approval Granted — The U.S. Federal Trade Commission approved Aurobindo Pharma USA’s $250 million acquisition of Lannett Company LLC, clearing the final regulatory hurdle.

## Recent coverage (1 stories)

### FTC OKs Aurobindo’s $250M Lannett Buy, Boosting Complex Generics
2026-07-27 04:41:50 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Aurobindo Pharma’s US subsidiary receives FTC clearance for its $250 million cash-free acquisition of Lannett, adding a complex generics and controlled substances portfolio expected to be immediately accretive to EPS and generate significant synergies.
Full story: https://getbiobrief.com/story/aurobindo-lannett-ftc-approval-pharma-deal

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.